ProfileGDS5678 / 1459873_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 43% 43% 43% 44% 43% 41% 41% 40% 43% 44% 43% 44% 43% 43% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.037143
GSM967853U87-EV human glioblastoma xenograft - Control 23.0072143
GSM967854U87-EV human glioblastoma xenograft - Control 33.0075743
GSM967855U87-EV human glioblastoma xenograft - Control 42.9609744
GSM967856U87-EV human glioblastoma xenograft - Control 52.9546143
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0399741
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0083341
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9053740
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9778343
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9952544
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9870443
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9803644
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9963743
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9956443